The Follow the Money Team’s new report on Pfizer’s financials, based on Pfizer’s Q1 2023 reporting, offers many important insights: Pfizer reports that its mRNA COVID vaccine, Comirnaty®, manufacturing activities, performed on behalf of BioNTech, dropped 89% to only $5 million quarter-over-quarter. In its Q1 2023 report, Pfizer assumes no growth in market share for […]
Report 63: In Q3 2022, Pfizer Wrote Off $450 Million of Expired or Expiring COVID-19-Related Inventory.
Despite generating over $100 billion in revenue in 2022, Pfizer’s stock has dropped precipitously. Pfizer’s revenue was relatively flat, hovering between $41 billion and $51 billion, from 2014 to 2020. Then, its mRNA COVID-19 “vaccine” was awarded Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) on December 11, 2020. On its Q2 […]